Profluent Bio vs Circle Pharma
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI protein design company released OpenCRISPR-1, the first gene editor designed entirely by AI; raised $35M developing novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space beyond what evolution has produced.
About
Profluent Bio is an AI protein design company founded in 2022 by former Meta AI researcher Ali Madani, raising $35M in seed and Series A funding. The company trains large generative models on biological sequence data to design novel proteins with specific structural and functional properties, analogous to how large language models generate text. Profluent made scientific history in 2024 by publishing OpenCRISPR-1, the first gene editor designed entirely by AI rather than adapted from natural organisms, which the company released open source for non-commercial research. The platform enables design of novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space far beyond what evolution has produced. Profluent works with pharmaceutical and agricultural biotechnology companies that need custom protein tools for research and therapeutic development. The company represents a fundamental advance in moving protein engineering from directed evolution and rational design toward generative AI-driven discovery.
Circle Pharma develops orally deliverable macrocycle drug candidates targeting intracellular protein-protein interactions in cancer; raised $90M Series B in 2023 led by Novo Holdings and Foresite Capital; headquartered in San Francisco;
About
Circle Pharma is a clinical-stage biopharmaceutical company founded in 2016 by Matthew Jacobson, Siegfried Bhagwati, and Grace Aldrovandi, headquartered in San Francisco, California. The company is developing a new class of therapeutics — cell-permeable macrocycles — designed to inhibit intracellular protein-protein interactions (PPIs) that have historically been considered "undruggable." Protein-protein interactions control critical cellular processes including cell division, apoptosis (programmed cell death), and gene expression. Dysregulation of these interactions drives many cancers, but their large, flat interaction surfaces are difficult to block with small molecules, and biologics (antibodies) cannot cross cell membranes to reach intracellular targets. Circle Pharma's macrocycles are medium-sized ring-shaped molecules engineered to be both cell-permeable and orally bioavailable — a combination rarely achieved — enabling them to reach and inhibit these targets.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.